267.40
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$261.07
Offen:
$261.92
24-Stunden-Volumen:
1.34M
Relative Volume:
1.48
Marktkapitalisierung:
$39.21B
Einnahmen:
$5.02B
Nettoeinkommen (Verlust:
$1.31B
KGV:
30.01
EPS:
8.91
Netto-Cashflow:
$1.56B
1W Leistung:
+6.11%
1M Leistung:
+5.41%
6M Leistung:
+8.11%
1J Leistung:
+29.00%
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
267.40 | 36.95B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
ISRG
Intuitive Surgical Inc
|
511.00 | 183.59B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
181.28 | 51.10B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
88.66 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
WST
West Pharmaceutical Services Inc
|
218.90 | 15.88B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
2025-01-16 | Eingeleitet | Goldman | Buy |
2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
2024-12-13 | Eingeleitet | Stifel | Hold |
2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | Herabstufung | Needham | Buy → Hold |
2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | Hochstufung | Needham | Hold → Buy |
2023-09-05 | Herabstufung | UBS | Buy → Neutral |
2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | Eingeleitet | UBS | Buy |
2023-04-14 | Eingeleitet | Mizuho | Buy |
2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
2022-10-12 | Eingeleitet | Jefferies | Hold |
2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
2021-08-02 | Herabstufung | Needham | Buy → Hold |
2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
2021-06-21 | Bestätigt | Needham | Buy |
2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
2021-03-16 | Hochstufung | Needham | Hold → Buy |
2020-11-02 | Hochstufung | UBS | Neutral → Buy |
2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | Eingeleitet | CLSA | Underperform |
2020-01-31 | Herabstufung | UBS | Buy → Neutral |
2020-01-10 | Eingeleitet | Oppenheimer | Perform |
2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | Hochstufung | UBS | Neutral → Buy |
2019-07-16 | Herabstufung | UBS | Buy → Neutral |
2019-05-06 | Hochstufung | UBS | Neutral → Buy |
2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
What analysts say about ResMed Inc. stockSkyrocketing investment returns - jammulinksnews.com
Is ResMed Inc. a good long term investmentMarket-beating returns - jammulinksnews.com
ResMed Inc. Stock Analysis and ForecastMarket-leading capital gains - jammulinksnews.com
What drives ResMed Inc. stock priceConsistently high returns - jammulinksnews.com
ResMed stock hits 52-week high at 263.62 USD By Investing.com - Investing.com South Africa
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research® - GlobeNewswire Inc.
Published on: 2025-07-19 18:08:41 - jammulinksnews.com
What makes ResMed Inc. stock attractive to long term investorsTrend Based Entry Alerts - beatles.ru
This ResMed Insider Reduced Their Stake By 72% - simplywall.st
This Pick Withstood the GLP-1 Challenge. Stick With the Stock. - Barron's
Analyst Expectations For ResMed's Future - Nasdaq
ResMed (RMD) Price Target Increased to $270 by Mizuho Analyst | - GuruFocus
Brokers Set Expectations for ResMed's Q1 Earnings (NYSE:RMD) - MarketBeat
RBC Upgrades ResMed to Outperform From Sector Perform, Adjusts Price Target to $294 From $255 - MarketScreener
ResMed's Trading Volume Surges 78.7% to 2.35 Billion, Stock Price Drops 0.11% Placing 406th in Market Rankings - AInvest
ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - 富途牛牛
ResMed CEO Executes Stock Transactions Under Rule 10b5-1 Plan - TipRanks
Resmed CEO Farrell sells $2.06 million in stock By Investing.com - Investing.com Canada
Resmed Insider Sold Shares Worth $2,056,076, According to a Recent SEC Filing - MarketScreener
ResMed Inc. Officer Plans Sale of Common Stock Under Rule 144 - TipRanks
With 75% institutional ownership, ResMed Inc. (NYSE:RMD) is a favorite amongst the big guns - simplywall.st
ResMed CFO Reports Changes in Stock Ownership - TipRanks
ResMed to Release Q4 2025 Financial Results on July 31, 2025, via Webcast - AInvest
ResMed Executives Sell Shares Under Pre-arranged Trading Plans - TradingView
ResMed Director Announces Further Share Sale - TipRanks
ResMed Chief Legal Officer Sells Shares - MarketScreener
Resmed Inc Officer Files Notice for Stock Sale Under Rule 144 - TipRanks
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 | RMD Stock News - GuruFocus
Resmed Announces Fourth Quarter Fiscal Year 2025 Financial Results Release and Webcast Details - Quiver Quantitative
ResMed (NYSE:RMD) Shows Growth in ROCE and Business Efficiency NYSE Composite - Kalkine Media
ResMed (NYSE:RMD) Could Become A Multi-Bagger - Yahoo Finance
Zacks.com featured highlights Sprouts Farmers Market, Adobe, GE Aerospace and ResMed - Yahoo Finance
All You Need to Know About ResMed (RMD) Rating Upgrade to Buy - Yahoo Finance
Is the ResMed share price still cheap? What the numbers say - The Motley Fool Australia
ResMed’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Bi Level Automatic Ventilator Market Is Booming Worldwide 2025-2032 | ResMed Inc., Philips Healthcare, Medtronic Plc - openPR.com
ResMed Stock: Is RMD Outperforming the Healthcare Sector? - MSN
ResMed Inc. (RMD) Investor Outlook: Analyzing Growth Potential Amidst a 6% Upside - DirectorsTalk Interviews
ResMed Stock: Is RMD Outperforming The Healthcare Sector? - Barchart.com
Resmed CEO Michael Farrell sells shares worth $2.01 million By Investing.com - Investing.com South Africa
ResMed: A Mixed Bag for Investors Amid Rising Competition - The Globe and Mail
Resmed CEO Michael Farrell sells shares worth $2.01 million - Investing.com
ResMed CEO Sells Shares Worth $2 Million - MarketScreener
ResMed Inc Reports Change in Beneficial Ownership - TipRanks
ResMed: A Sleeping Giant Hiding In Plain Sight (NYSE:RMD) - Seeking Alpha
Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell? - MSN
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed director Peter Farrell sells $494,640 in stock By Investing.com - Investing.com Nigeria
ResMed director Peter Farrell sells $494,640 in stock - Investing.com Australia
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):